Synergistic effect of gefitinib and rofecoxib in mesothelioma cells

BACKGROUND: Malignant mesothelioma (MM) is an aggressive tumor that is resistant to conventional modes of treatment with chemotherapy, surgery or radiation. Research into the molecular pathways involved in the development of MM should yield information that will guide therapeutic decisions. Epiderma...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoppoloni, Daniela, Canino, Claudia, Cardillo, Irene, Verdina, Alessandra, Baldi, Alfonso, Sacchi, Ada, Galati, Rossella
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828989/
https://www.ncbi.nlm.nih.gov/pubmed/20122271
http://dx.doi.org/10.1186/1476-4598-9-27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828989/
https://www.ncbi.nlm.nih.gov/pubmed/20122271
http://dx.doi.org/10.1186/1476-4598-9-27

Ejemplares similares